Literature DB >> 18509013

Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations.

Jessie Shih1, Saul A Datwyler, Stephen C Hsu, Matthew S Matias, David P Pacenti, Christian Lueders, Christian Mueller, Oliver Danne, Martin Möckel.   

Abstract

BACKGROUND: Myeloperoxidase (MPO) has shown potential as a marker for cardiovascular disease. Limited studies have been published with a variety of sample types, resulting in a wide range of MPO values. Little is known or understood about the impact of collection tube type and preanalytical handling of specimens for MPO determination.
METHOD: MPO concentration was determined by use of the ARCHITECT(R) MPO research use assay, which is currently under development. Samples were collected into multiple anticoagulant collection tubes from donors and patients presenting to the emergency department with symptoms of acute coronary syndromes. Whole blood was stored on ice or at room temperature for predetermined time periods. We also evaluated serum and plasma after centrifugation followed by storage at room temperature, 2-8 degrees C, and below -10 degrees C.
RESULTS: Baseline sample concentrations were dependent on collection tube type as well as handling conditions. MPO concentrations were consistently higher in samples collected in serum and heparin plasma tubes than in samples in EDTA or citrate tubes. Spike recovery was acceptable in all sera and plasma tested, indicating that the increased MPO concentrations were not due directly to an anticoagulant interference.
CONCLUSIONS: The collection tube type and preanalytical handling are critical for accurate and consistent MPO measurement. The preferred anticoagulant and tubes are the EDTA or EDTA plasma preparation tube. MPO concentrations in samples collected in these tubes are stable before centrifugation as whole blood as well as plasma after processing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509013     DOI: 10.1373/clinchem.2007.101568

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  16 in total

Review 1.  Myeloperoxidase production by macrophage and risk of atherosclerosis.

Authors:  Mahir Karakas; Wolfgang Koenig
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

2.  Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.

Authors:  Benjamin M Scirica; Marc S Sabatine; Petr Jarolim; Sabina A Murphy; James L de Lemos; Eugene Braunwald; David A Morrow
Journal:  Eur Heart J       Date:  2010-12-22       Impact factor: 29.983

Review 3.  Biomarker tests for risk assessment in coronary artery disease: will they change clinical practice?

Authors:  Johannes Mair; Allan S Jaffe
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

Review 4.  Emerging inflammatory markers for assessing coronary heart disease risk.

Authors:  Marshall A Corson
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

Review 5.  Reactive oxygen species in cardiovascular disease.

Authors:  Koichi Sugamura; John F Keaney
Journal:  Free Radic Biol Med       Date:  2011-05-15       Impact factor: 7.376

6.  Predictive value of the novel risk score BETTER (BiomarkErs and compuTed Tomography scorE on Risk stratification) for patients with unstable angina.

Authors:  Y Xia; Y Xia; K Xu; Y Ma; D Pan; T Xu; L Lu; D Li
Journal:  Herz       Date:  2014-08-31       Impact factor: 1.443

Review 7.  Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease.

Authors:  Kai Chen; John F Keaney
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

8.  The role of myeloperoxidase (MPO) for prognostic evaluation in sensitive cardiac troponin I negative chest pain patients in the emergency department.

Authors:  Julia Searle; Jessie Shih; Reinhold Muller; Jörn O Vollert; Christian Müller; Oliver Danne; Saul Datwyler; Martin Möckel
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09

9.  Global stability of plasma proteomes for mass spectrometry-based analyses.

Authors:  Lisa J Zimmerman; Ming Li; Wendell G Yarbrough; Robbert J C Slebos; Daniel C Liebler
Journal:  Mol Cell Proteomics       Date:  2012-02-01       Impact factor: 5.911

10.  A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma.

Authors:  Reece J Goiffon; Sara C Martinez; David Piwnica-Worms
Journal:  Nat Commun       Date:  2015-02-10       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.